PAD4-IN-3 is a PAD4 inhibitor with in vitro and in vivo antitumor activity; it is conjugated to an RGD peptide-modified chitosan (K-CRGDV) to form an enhanced oxidative stress-responsive nanotherapeutic agent (K-CRGDV-PAD4-IN-3) that actively targets tumors, inhibits PAD4 activity, blocks neutrophil extracellular trap (NET) formation, and modulates the tumor immune microenvironment in response to the tumor microenvironment.